Theravance To Buy Back $250 Mln Of Shares

Theravance Biopharma, Inc. (TBPH), a company focused on serious lung diseases, said on Monday that it has started a $250 million capital return program.

With this move, Theravance has inked a deal to buy back its 9.6 million shares from GSK Plc (GSK), for $9.75 per share.

The share purchase is expected to be closed on September 20.

The drug maker said that it aims to start a Dutch auction tender offer to buy around $95 million of its shares in the near term.

Subsequent to the close of the tender offer, Theravance also intends to repurchase around $60 million of its shares by 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT